Jeffrey M. Skolnik

Learn More
  • Burgering, B M T Bos, +27 authors R J Gbg
  • 1997
in vitro and in vivo association assays. The GST–cytoplasmic region of EGFR fusion proteins (amino acids 930–1,220, which do not include Lys 721, a key residue in the ATP-binding site) were generated as described 28. The in vitro Jak2 assay was done as before 2 , with minimal modification. Proteins immobilized on anti-Jak2 antibody were mixed with 95 ␮l of(More)
Previous exploration of oncology study design efficiency has focused on Markov processes alone (probability-based events) without consideration for time dependencies. Barriers to study completion include time delays associated with patient accrual, inevaluability (IE), time to dose limiting toxicities (DLT) and administrative and review time. Discrete event(More)
PURPOSE KRAS is the most commonly mutated oncogene in human tumors. KRAS-mutant cells may exhibit resistance to the allosteric MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) and allosteric AKT inhibitors (such as MK-2206), the combination of which may overcome resistance to both monotherapies. EXPERIMENTAL DESIGN We conducted a dose/schedule-finding(More)
Running title: Targeting KRAS signalling through MEK and AKT. Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 2 Preliminary data were presented in part as oral and poster presentations at the 47th and 48th and may hold stock/stock options in the company. JMS, PS, and ML were employees of AstraZeneca,(More)
This systematic literature review describes adverse events (AEs) among patients with soft tissue sarcoma (STS) who received second-line or later anticancer therapies. Searches were conducted in PubMed, EMBASE, and Cochrane Central Register of Controlled Trials for studies of adults with advanced or metastatic STS who received systemic anticancer therapy(More)
Seven years after the launch of the European Paediatric Medicine Regulation, limited progress in paediatric oncology drug development remains a major concern amongst stakeholders - academics, industry, regulatory authorities, parents, patients and caregivers. Restricted increases in early phase paediatric oncology trials, legal requirements and regulatory(More)
This investigation evaluated the impact of potential drug interactions on the incidence of reported toxicities seen with common dosing patterns in children with cancer, with the intent of being able to screen and reduce the incidence of adverse drug reactions (ADRs) in the future. Toxicity reported in pediatric cancer patients treated at the Children’s(More)
Purpose: KRAS is the most commonly mutated oncogene in human tumors. KRAS-mutant cells may exhibit resistance to the allosteric MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) and allosteric AKT inhibitors (such as MK-2206), the combination of which may overcome resistance to both monotherapies. Experimental Design: We conducted a dose/schedule-finding(More)
  • 1